Discontinue use if markedly elevated creatine kinase (>5 x ULN) occurs or if muscular symptoms are severe; ILD is suspected. Not to be used in patients w/ acute, serious condition suggestive of myopathy or predisposing to renal failure development secondary to rhabdomyolysis eg, sepsis, hypotension, major surgery, trauma, severe metabolic, endocrine & electrolyte disorders or uncontrolled seizures. Predisposing factors for myopathy/rhabdomyolysis eg, hypothyroidism, history of hereditary muscular disorders or toxicity w/ another HMG-CoA reductase inhibitor or fibrate, situations increasing plasma levels. Immune-mediated necrotising myopathy; DM, HTN. Monitor lipid levels periodically. Assess renal function during routine follow-up. Perform LFTs prior to & 3 mth following initiation. Asian patients; genetic polymorphisms. Avoid excessive alcohol consumption. Not to be taken by patients w/ galactose intolerance, Lapp lactase deficiency or glucose-galactose malabsorption. Not recommended in combination w/ gemfibrozil, PIs. Concomitant use w/ fibrates, niacin, fibric acid derivatives eg, ciclosporin, nicotinic acid, azole antifungals, macrolides. History of hepatic disease. Severe renal impairment. Women of childbearing potential should use effective contraception. Pregnancy & lactation. Childn <10 yr. Elderly >70 yr.